PORTOLA PHARMACEUTICALS INC
PORTOLA PHARMACEUTICALS INC (PTLA): 4 pipeline candidates · ~16 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
15.5 months
0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for PORTOLA PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$200.6M
Quarterly Burn
$71.1M
Runway
15.5 mo
Revenue
$26.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| andexxa | Approved |
| bevyxxa | Approved |
| cerdulatinib | Preclinical |
| prt2761 | Phase 2 |
Frequently asked questions
How many drug candidates are in PORTOLA PHARMACEUTICALS INC's pipeline?
PORTOLA PHARMACEUTICALS INC (PTLA) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PORTOLA PHARMACEUTICALS INC's lead drug candidate?
PORTOLA PHARMACEUTICALS INC's most advanced tracked candidate is andexxa (Approved) for reversal of anticoagulation in patients treated with rivaroxaban and apixaban when reversal is needed due to life-threatening or uncontrolled bleeding.
What is PORTOLA PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PORTOLA PHARMACEUTICALS INC has approximately 15.5 months of cash runway.
Who is the CEO of PORTOLA PHARMACEUTICALS INC?
Transition Committee is the chief executive officer of PORTOLA PHARMACEUTICALS INC (PTLA).
Get the full picture on PORTOLA PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.